Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2015
|
| gptkbp:ATCCode |
gptkb:B01AC10
|
| gptkbp:CASNumber |
gptkb:163706-06-7
|
| gptkbp:chemicalFormula |
C17H25F3N5O12P3
|
| gptkbp:contraindication |
active bleeding
history of stroke or transient ischemic attack |
| gptkbp:drugClass |
gptkb:anticoagulant
|
| gptkbp:genericName |
gptkb:cangrelor
|
| gptkbp:halfLife |
3-6 minutes
|
| https://www.w3.org/2000/01/rdf-schema#label |
Kengreal
|
| gptkbp:indication |
patients undergoing percutaneous coronary intervention (PCI)
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Chiesi_USA
|
| gptkbp:mechanismOfAction |
P2Y12 platelet inhibitor
|
| gptkbp:pregnancyCategory |
Not assigned (US)
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
bleeding
dyspnea hypersensitivity reactions |
| gptkbp:usedFor |
reducing risk of periprocedural thrombotic events
|
| gptkbp:bfsParent |
gptkb:AR-C
|
| gptkbp:bfsLayer |
6
|